✦ LIBER ✦

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

✍ Scribed by Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelson, M Dror; Negrier, Sylvie; Oudard, Stephane; Gore, Martin E; Tarazi, Jamal; Hariharan, Subramanian; Chen, Connie; Rosbrook, Brad; Kim, Sinil; Rini, Brian I

Book ID: 120458619
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 316 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70093-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

81 Updated results of the phase 3 AXIS t

81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

✍ B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

SUNITINIB AS FIRST-LINE TREATMENT FOR ME

SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL

✍ S. Oudard; R.J. Motzer; M.D. Michaelson; T.E. Hutson; P. Tomczak; R.M. Bukowski; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Randomized phase 3 trial of interferon g

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

✍ David S. Alberts; Christian Marth; Ronald D. Alvarez; Gary Johnson; Mariusz Bidz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 233 KB

6501 ORAL Global Lung Oncology Branch tr

6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Rolski, J.; Grodzki, T.; Schneider, C.P.; Zatloukal, P.; Reck, M.; Aitini, E.; T 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB